Bangladesh has entered into a deal with the Serum Institute of India (SII) to acquire 30 million doses of a potential vaccine being developed by AstraZeneca for Covid-19.SII and Bangladesh’s drugmaker Beximco Pharma signed a Memorandum of Understanding (MoU) for priority delivery of the vaccine doses.Under the deal, Beximco will purchase five milli...

Details Background: The Gamaleya Research Institute in Russia is testing their non-replicating viral vector COVID-19 vaccine candidate, Sputnik V (formerly Gam-COVID-Vac), in two Phase 1/2 trials. The trials recruited about 38 participants each to receive the vaccine candidate (NCT04436471) (NCT04437875).   Outcomes...

Pharmaceutical company AstraZeneca and Oxford University have resumed clinical trials of their COVID-19 vaccine candidate in the United Kingdom after a brief global pause in testing. AstraZeneca put a hold on its COVID-19 clinical trials worldwide this week while it investigated an adverse reaction in...

Oxford researchers halt vaccine trial while adverse reaction is investigated One of the leading covid-19 vaccine candidate trials has been voluntarily paused as part of a standard review process triggered by a “single event of an unexplained illness that occurred in the UK phase III trial.” The...